Matthew Harrison
Stock Analyst at Morgan Stanley
(3.47)
# 1,001
Out of 4,412 analysts
503
Total ratings
49.35%
Success rate
3.09%
Average return
Main Sectors:
63 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Equal-Weight | $80 → $78 | $65.42 | +19.23% | 24 | Apr 26, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $112 | $80.91 | +38.43% | 17 | Apr 26, 2024 | |
| PHVS Pharvaris | Maintains: Overweight | $34 | $23.35 | +45.61% | 14 | Apr 22, 2024 | |
| GMAB Genmab | Maintains: Underweight | $32 | $28.15 | +13.68% | 20 | Mar 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,104 → $1,115 | $883.20 | +26.25% | 29 | Mar 13, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $607 → $586 | $372.80 | +57.19% | 12 | Nov 30, 2023 | |
| BIIB Biogen | Maintains: Overweight | $361 → $373 | $208.90 | +78.55% | 32 | Nov 10, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $359 → $364 | $397.48 | -8.42% | 14 | Nov 8, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Overweight | $55 → $38 | $11.06 | +243.58% | 3 | Nov 7, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Overweight | $42 → $38 | $42.47 | -10.53% | 6 | Nov 2, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $183 → $146 | $128.77 | +13.38% | 26 | Oct 31, 2023 | |
| CNTA Centessa Pharmaceuticals | Upgrades: Equal-Weight | $4 → $8 | $8.92 | -10.31% | 8 | Oct 26, 2023 | |
| BGNE BeiGene | Maintains: Overweight | $321 → $319 | $153.58 | +107.71% | 14 | Aug 29, 2023 | |
| IOBT IO Biotech | Maintains: Overweight | $11 → $7 | $1.42 | +392.96% | 3 | Aug 15, 2023 | |
| PRME Prime Medicine | Maintains: Equal-Weight | $21 → $19 | $4.43 | +329.38% | 3 | Aug 14, 2023 | |
| TNYA Tenaya Therapeutics | Maintains: Overweight | $13 → $14 | $4.31 | +224.83% | 4 | Aug 10, 2023 | |
| ALEC Alector | Reiterates: Equal-Weight | $10 | $5.25 | +90.48% | 6 | Aug 7, 2023 | |
| MRNA Moderna | Maintains: Equal-Weight | $128 → $123 | $107.97 | +13.92% | 19 | Aug 4, 2023 | |
| INSM Insmed | Reiterates: Overweight | $41 | $24.80 | +65.32% | 7 | Aug 4, 2023 | |
| TSVT 2seventy bio | Downgrades: Equal-Weight | $25 → $13 | $4.26 | +205.52% | 8 | Jul 28, 2023 | |
| LEGN Legend Biotech | Maintains: Overweight | $65 → $85 | $45.30 | +87.64% | 8 | Jul 20, 2023 | |
| BLUE bluebird bio | Reiterates: Underweight | $3 | $0.92 | +225.10% | 17 | Jul 11, 2023 | |
| CMCSA Comcast | Reiterates: Buy | $46 | $38.57 | +19.26% | 1 | Apr 24, 2023 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $61 → $63 | $15.43 | +308.30% | 8 | Apr 12, 2023 | |
| VIGL Vigil Neuroscience | Maintains: Equal-Weight | $12 → $13 | $2.71 | +379.70% | 4 | Mar 27, 2023 | |
| IVVD Invivyd | Maintains: Underweight | $2 → $1 | $2.15 | -53.49% | 3 | Mar 27, 2023 | |
| INVA Innoviva | Maintains: Underweight | $13 → $10 | $15.26 | -34.47% | 8 | Mar 3, 2023 | |
| FULC Fulcrum Therapeutics | Downgrades: Equal-Weight | $27 → $8 | $7.14 | +12.04% | 8 | Feb 28, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $57 → $44 | $28.76 | +52.99% | 16 | Feb 27, 2023 | |
| FUSN Fusion Pharmaceuticals | Maintains: Overweight | $19 → $10 | $21.42 | -53.31% | 3 | Jan 27, 2023 | |
| SANA Sana Biotechnology | Maintains: Overweight | $15 → $13 | $8.72 | +49.08% | 3 | Jan 24, 2023 | |
| LYEL Lyell Immunopharma | Maintains: Equal-Weight | $7 → $4 | $2.17 | +84.33% | 4 | Jan 24, 2023 | |
| EDIT Editas Medicine | Maintains: Underweight | $8 → $7 | $5.32 | +31.58% | 10 | Jan 24, 2023 | |
| BOLT Bolt Biotherapeutics | Maintains: Equal-Weight | $5 → $3 | $1.11 | +170.27% | 4 | Jan 24, 2023 | |
| BNTX BioNTech SE | Maintains: Equal-Weight | $203 → $216 | $87.21 | +147.68% | 8 | Jan 24, 2023 | |
| AVIR Atea Pharmaceuticals | Maintains: Underweight | $7 → $4 | $3.71 | +7.82% | 7 | Jan 24, 2023 | |
| ADCT ADC Therapeutics | Maintains: Equal-Weight | $7 → $5 | $4.34 | +15.21% | 8 | Jan 24, 2023 | |
| ADAG Adagene | Maintains: Overweight | $7 → $5 | $2.39 | +109.21% | 6 | Jan 24, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $178 → $182 | $159.62 | +14.02% | 7 | Dec 6, 2022 | |
| KOD Kodiak Sciences | Maintains: Equal-Weight | $12 → $9 | $3.28 | +174.39% | 9 | Nov 14, 2022 | |
| AKRO Akero Therapeutics | Maintains: Equal-Weight | $30 → $40 | $19.74 | +102.63% | 5 | Nov 7, 2022 | |
| AMGN Amgen | Maintains: Overweight | $279 → $282 | $269.98 | +4.45% | 20 | Nov 4, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $220 → $210 | $143.31 | +46.54% | 7 | Oct 28, 2022 | |
| ALVR AlloVir | Maintains: Overweight | $32 → $27 | $0.80 | +3,287.28% | 5 | Sep 9, 2022 | |
| PFE Pfizer | Maintains: Equal-Weight | $55 → $52 | $25.40 | +104.72% | 5 | May 4, 2022 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $175 → $173 | $146.14 | +18.38% | 3 | Apr 6, 2022 | |
| SAGE Sage Therapeutics | Maintains: Equal-Weight | $61 → $57 | $13.69 | +316.36% | 4 | Mar 10, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $156 → $120 | $44.24 | +171.25% | 5 | Feb 1, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Equal-Weight | $145 → $148 | $38.97 | +279.78% | 9 | Jan 7, 2022 | |
| MRK Merck & Co. | Maintains: Equal-Weight | n/a | $131.20 | - | 4 | Nov 29, 2021 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | n/a | $44.85 | - | 2 | Oct 12, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | n/a | $2.39 | - | 2 | Aug 18, 2021 | |
| RPRX Royalty Pharma | Maintains: Equal-Weight | n/a | $28.00 | - | 1 | Aug 16, 2021 | |
| OGN Organon & Co. | Maintains: Equal-Weight | n/a | $18.55 | - | 1 | Aug 16, 2021 | |
| LLY Eli Lilly | Maintains: Overweight | n/a | $733.51 | - | 1 | Aug 4, 2021 | |
| TV Grupo Televisa, S.A.B. | Initiates: Buy | n/a | $3.16 | - | 1 | Jun 24, 2021 | |
| RGNX REGENXBIO | Maintains: Overweight | n/a | $16.19 | - | 4 | Mar 8, 2021 | |
| HBAN Huntington Bancshares | Maintains: Equal-Weight | n/a | $13.55 | - | 1 | Feb 24, 2021 | |
| UBX Unity Biotechnology | Downgrades: Equal-Weight | n/a | $1.50 | - | 2 | Aug 18, 2020 | |
| EVLO Evelo Biosciences | Downgrades: Equal-Weight | n/a | $0.05 | - | 1 | May 21, 2020 | |
| INCY Incyte | Maintains: Equal-Weight | n/a | $51.68 | - | 1 | Jan 6, 2020 | |
| RDUS Radius Health | Maintains: Overweight | n/a | $17.90 | - | 4 | Oct 11, 2018 | |
| CYTK Cytokinetics | Assumes: Equal-Weight | n/a | $65.34 | - | 4 | Sep 10, 2018 |
Gilead Sciences
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $80 → $78
Current: $65.42
Upside: +19.23%
BioMarin Pharmaceutical
Apr 26, 2024
Maintains: Overweight
Price Target: $115 → $112
Current: $80.91
Upside: +38.43%
Pharvaris
Apr 22, 2024
Maintains: Overweight
Price Target: $34
Current: $23.35
Upside: +45.61%
Genmab
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $28.15
Upside: +13.68%
Regeneron Pharmaceuticals
Mar 13, 2024
Maintains: Overweight
Price Target: $1,104 → $1,115
Current: $883.20
Upside: +26.25%
argenx SE
Nov 30, 2023
Maintains: Overweight
Price Target: $607 → $586
Current: $372.80
Upside: +57.19%
Biogen
Nov 10, 2023
Maintains: Overweight
Price Target: $361 → $373
Current: $208.90
Upside: +78.55%
Vertex Pharmaceuticals
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $359 → $364
Current: $397.48
Upside: -8.42%
Zentalis Pharmaceuticals
Nov 7, 2023
Maintains: Overweight
Price Target: $55 → $38
Current: $11.06
Upside: +243.58%
Cerevel Therapeutics Holdings
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $42.47
Upside: -10.53%
Sarepta Therapeutics
Oct 31, 2023
Maintains: Overweight
Price Target: $183 → $146
Current: $128.77
Upside: +13.38%
Centessa Pharmaceuticals
Oct 26, 2023
Upgrades: Equal-Weight
Price Target: $4 → $8
Current: $8.92
Upside: -10.31%
BeiGene
Aug 29, 2023
Maintains: Overweight
Price Target: $321 → $319
Current: $153.58
Upside: +107.71%
IO Biotech
Aug 15, 2023
Maintains: Overweight
Price Target: $11 → $7
Current: $1.42
Upside: +392.96%
Prime Medicine
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $4.43
Upside: +329.38%
Tenaya Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $13 → $14
Current: $4.31
Upside: +224.83%
Alector
Aug 7, 2023
Reiterates: Equal-Weight
Price Target: $10
Current: $5.25
Upside: +90.48%
Moderna
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $128 → $123
Current: $107.97
Upside: +13.92%
Insmed
Aug 4, 2023
Reiterates: Overweight
Price Target: $41
Current: $24.80
Upside: +65.32%
2seventy bio
Jul 28, 2023
Downgrades: Equal-Weight
Price Target: $25 → $13
Current: $4.26
Upside: +205.52%
Legend Biotech
Jul 20, 2023
Maintains: Overweight
Price Target: $65 → $85
Current: $45.30
Upside: +87.64%
bluebird bio
Jul 11, 2023
Reiterates: Underweight
Price Target: $3
Current: $0.92
Upside: +225.10%
Comcast
Apr 24, 2023
Reiterates: Buy
Price Target: $46
Current: $38.57
Upside: +19.26%
Denali Therapeutics
Apr 12, 2023
Maintains: Overweight
Price Target: $61 → $63
Current: $15.43
Upside: +308.30%
Vigil Neuroscience
Mar 27, 2023
Maintains: Equal-Weight
Price Target: $12 → $13
Current: $2.71
Upside: +379.70%
Invivyd
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $2.15
Upside: -53.49%
Innoviva
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $15.26
Upside: -34.47%
Fulcrum Therapeutics
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $7.14
Upside: +12.04%
Galapagos NV
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $57 → $44
Current: $28.76
Upside: +52.99%
Fusion Pharmaceuticals
Jan 27, 2023
Maintains: Overweight
Price Target: $19 → $10
Current: $21.42
Upside: -53.31%
Sana Biotechnology
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $8.72
Upside: +49.08%
Lyell Immunopharma
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $4
Current: $2.17
Upside: +84.33%
Editas Medicine
Jan 24, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $5.32
Upside: +31.58%
Bolt Biotherapeutics
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.11
Upside: +170.27%
BioNTech SE
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $87.21
Upside: +147.68%
Atea Pharmaceuticals
Jan 24, 2023
Maintains: Underweight
Price Target: $7 → $4
Current: $3.71
Upside: +7.82%
ADC Therapeutics
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.34
Upside: +15.21%
Adagene
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $2.39
Upside: +109.21%
AbbVie
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $159.62
Upside: +14.02%
Kodiak Sciences
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $3.28
Upside: +174.39%
Akero Therapeutics
Nov 7, 2022
Maintains: Equal-Weight
Price Target: $30 → $40
Current: $19.74
Upside: +102.63%
Amgen
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $269.98
Upside: +4.45%
Alnylam Pharmaceuticals
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $143.31
Upside: +46.54%
AlloVir
Sep 9, 2022
Maintains: Overweight
Price Target: $32 → $27
Current: $0.80
Upside: +3,287.28%
Pfizer
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $25.40
Upside: +104.72%
Johnson & Johnson
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $146.14
Upside: +18.38%
Sage Therapeutics
Mar 10, 2022
Maintains: Equal-Weight
Price Target: $61 → $57
Current: $13.69
Upside: +316.36%
Ultragenyx Pharmaceutical
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $44.24
Upside: +171.25%
Biohaven Pharmaceutical Holding Company
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $38.97
Upside: +279.78%
Merck & Co.
Nov 29, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $131.20
Upside: -
Bristol-Myers Squibb Company
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $44.85
Upside: -
Taysha Gene Therapies
Aug 18, 2021
Maintains: Overweight
Price Target: n/a
Current: $2.39
Upside: -
Royalty Pharma
Aug 16, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $28.00
Upside: -
Organon & Co.
Aug 16, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $18.55
Upside: -
Eli Lilly
Aug 4, 2021
Maintains: Overweight
Price Target: n/a
Current: $733.51
Upside: -
Grupo Televisa, S.A.B.
Jun 24, 2021
Initiates: Buy
Price Target: n/a
Current: $3.16
Upside: -
REGENXBIO
Mar 8, 2021
Maintains: Overweight
Price Target: n/a
Current: $16.19
Upside: -
Huntington Bancshares
Feb 24, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $13.55
Upside: -
Unity Biotechnology
Aug 18, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $1.50
Upside: -
Evelo Biosciences
May 21, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $0.05
Upside: -
Incyte
Jan 6, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $51.68
Upside: -
Radius Health
Oct 11, 2018
Maintains: Overweight
Price Target: n/a
Current: $17.90
Upside: -
Cytokinetics
Sep 10, 2018
Assumes: Equal-Weight
Price Target: n/a
Current: $65.34
Upside: -